Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + hepatitis B immune globulin
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Entecavir + hepatitis B immune globulin (HBIG) is a combination therapy used primarily to prevent hepatitis B virus (HBV) recurrence in patients undergoing liver transplantation for HBV-related liver disease. Entecavir is a potent oral nucleoside analogue that inhibits the reverse transcriptase activity of HBV polymerase, blocking viral replication at multiple steps. Hepatitis B immune globulin is a human-derived antibody preparation that provides passive immunity by neutralizing circulating hepatitis B surface antigen (HBsAg). The combination of these two agents has demonstrated high efficacy in maintaining viral suppression and preventing virological recurrence after transplantation, with improved survival outcomes compared to older protocols. This regimen is considered standard of care for post-transplant prophylaxis against HBV reinfection[1][2].
- Other names
- entecavir + HBIG
02
Targets
HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on entecavir + hepatitis B immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + hepatitis B immune globulin.